Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
NCT07924436, Not applicable, Recruiting, Pamukkale University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT07924436 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 30 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Pamukkale University | ClinicalTrials.gov |
| Conditions | Obesity, Diabetes Mellitus, Type 2 | ClinicalTrials.gov |
| Interventions | Whole-Body Vibration Training | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Tibialis Anterior Muscle Activation | Baseline and after completion of the 8-week intervention | Bilateral tibialis anterior muscle activation will be measured using surface electromyography during level walking, tandem walking, and tandem standing. Root mean square (RMS) amplitudes will be normalized to the corresponding muscle- and side-specific maximal voluntary isometric contraction (MVIC) reference and expressed as %MVIC. For each side and task, both mean and maximum normalized RMS amplitudes will be calculated for each valid trial and averaged separately across three valid trials. Mean and maximum amplitudes will be analyzed separately; no composite score will be calculated. Changes will be calculated as the post-intervention value minus the corresponding baseline value and expressed in percentage points of MVIC. Right and left sides and the three tasks will be evaluated separately. | ClinicalTrials.gov |
| Primary | Change in Soleus Muscle Activation | Baseline and after completion of the 8-week intervention | Bilateral soleus muscle activation will be measured using surface electromyography during level walking, tandem walking, and tandem standing. Root mean square (RMS) amplitudes will be normalized to the corresponding muscle- and side-specific maximal voluntary isometric contraction (MVIC) reference and expressed as %MVIC. For each side and task, both mean and maximum normalized RMS amplitudes will be calculated for each valid trial and averaged separately across three valid trials. Mean and maximum amplitudes will be analyzed separately; no composite score will be calculated. Changes will be calculated as the post-intervention value minus the corresponding baseline value and expressed in percentage points of MVIC. Right and left sides and the three tasks will be evaluated separately. | ClinicalTrials.gov |
| Primary | Change in Medial Gastrocnemius Muscle Activation | Baseline and after completion of the 8-week intervention | Bilateral medial gastrocnemius muscle activation will be measured using surface electromyography during level walking, tandem walking, and tandem standing. Root mean square (RMS) amplitudes will be normalized to the corresponding muscle- and side-specific maximal voluntary isometric contraction (MVIC) reference and expressed as %MVIC. For each side and task, both mean and maximum normalized RMS amplitudes will be calculated for each valid trial and averaged separately across three valid trials. Mean and maximum amplitudes will be analyzed separately; no composite score will be calculated. Changes will be calculated as the post-intervention value minus the corresponding baseline value and expressed in percentage points of MVIC. Right and left sides and the three tasks will be evaluated separately. | ClinicalTrials.gov |
| Secondary | Change in Michigan Neuropathy Screening Instrument Questionnaire Score | Baseline and after completion of the 8-week intervention | Neuropathic symptoms will be assessed using the questionnaire section of the Michigan Neuropathy Screening Instrument in women with obesity, with and without type 2 diabetes. The questionnaire contains 15 yes/no items, of which 13 contribute to the total score. Scores range from 0 to 13, with higher scores indicating more neuropathic symptoms. Change will be calculated as the post-intervention score minus the baseline score. Negative changes indicate fewer reported symptoms. | ClinicalTrials.gov |
| Secondary | Change in Michigan Neuropathy Screening Instrument Physical Examination Score | Baseline and after completion of the 8-week intervention | Peripheral neuropathy signs will be assessed using the physical examination section of the Michigan Neuropathy Screening Instrument in women with obesity, with and without type 2 diabetes. Both feet will be examined for abnormal appearance, ulceration, ankle reflexes, vibration perception at the great toe, and monofilament sensation. The total score ranges from 0 to 10, with higher scores indicating more abnormal findings. Change will be calculated as the post-intervention score minus the baseline score. Negative changes indicate fewer clinical signs of neuropathy. | ClinicalTrials.gov |
| Secondary | Change in Timed Up and Go Test Performance | Baseline and after completion of the 8-week intervention | Functional mobility will be assessed using the Timed Up and Go test. The time required to rise from a chair, walk 3 meters, turn, return to the chair, and sit down will be recorded in seconds. Two trials will be performed at each assessment, and their mean completion time will be used for analysis. Lower values indicate better functional mobility. Change will be calculated as the post-intervention mean time minus the baseline mean time. Negative changes indicate improved performance. | ClinicalTrials.gov |
| Secondary | Change in Body Mass Index | Baseline and after completion of the 8-week intervention | Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared and expressed in kg/m². Body weight will be measured using the Tanita BC-418 analyzer. Change will be calculated as post-intervention BMI minus baseline BMI. | ClinicalTrials.gov |
| Secondary | Change in Total Body Fat Percentage | Baseline and after completion of the 8-week intervention | Total body fat percentage will be estimated using the Tanita BC-418 segmental bioelectrical impedance analyzer under standardized measurement conditions. Values will be expressed as a percentage of total body weight. Change will be calculated as the post-intervention value minus the baseline value and expressed in percentage points. Negative changes indicate a reduction in body fat percentage. | ClinicalTrials.gov |
| Secondary | Change in Total Fat-Free Mass | Baseline and after completion of the 8-week intervention | Total fat-free mass will be estimated using the Tanita BC-418 segmental bioelectrical impedance analyzer under standardized measurement conditions and expressed in kilograms. Fat-free mass includes all non-fat body components and is not equivalent to skeletal muscle mass. Change will be calculated as post-intervention fat-free mass minus baseline fat-free mass. | ClinicalTrials.gov |
| Secondary | Change in Segmental Predicted Muscle Mass | Baseline and after completion of the 8-week intervention | Segmental predicted muscle mass will be estimated using the Tanita BC-418 segmental bioelectrical impedance analyzer under standardized measurement conditions. Device-derived estimates will be recorded in kilograms for the right arm, left arm, right leg, left leg, and trunk. Each segment will be evaluated separately. Change will be calculated as the post-intervention value minus the baseline value for each segment. | ClinicalTrials.gov |
| Secondary | Change in Body Weight | Baseline and after completion of the 8-week intervention | Body weight will be measured in kilograms using the Tanita BC-418 analyzer under standardized measurement conditions. Change will be calculated as post-intervention weight minus baseline weight. Negative values indicate a reduction in body weight. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)